Effects of genetic engineering on the pharmacokinetics of antibodies

D. Colcher, A. Goel, G. Pavlinkova, G. Beresford, B. Booth, Surinder Kumar Batra

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Monoclonal antibodies (MAbs) may be considered 'magic bullets' due to their ability to recognize and eradicate malignant cells. MAbs, however, have practical limitations for their rapid application in the clinics. The structure of antibody molecules can be engineered to modify functional domains such as antigen-binding sites and/or effector functions. Advances in genetic engineering have provided rapid progress in the development of new immunoglobulin constructs of MAbs with defined research and therapeutic application. Recombinant antibody constructs are being engineered, such as human-mouse chimeric, domain-dispositioned, domain-deleted, humanized and single-chain Fv fragments. Genetically-engineered antibodies differ in size and rate of catabolism. Pharmacokinetic studies show that the intact IgG (150 kD), enzymatically derived fragments Fab' (50 kD) and single chain Fv (28 kD) have different clearance rates. These antibody forms clear 50% from the blood pool in 2.1 days, 30 minutes and 10 minutes, respectively. Genetically- engineered antibodies make anew class of immunotherapeutic tracers for cancer treatment.

Original languageEnglish (US)
Pages (from-to)132-139
Number of pages8
JournalQuarterly Journal of Nuclear Medicine
Volume43
Issue number2
StatePublished - Jul 19 1999

Fingerprint

Genetic Engineering
Pharmacokinetics
Antibodies
Single-Chain Antibodies
Monoclonal Antibodies
Immunoglobulin Variable Region
Therapeutic Human Experimentation
Immunoglobulin Fab Fragments
Magic
Immunoglobulins
Immunoglobulin G
Binding Sites
Antigens
Neoplasms

Keywords

  • Antibodies
  • Antibodies monoclonal
  • Colon carcinoma xenografts
  • Immunoglobulin fragments
  • Monoclonal biosynthesis
  • Radioimmunodetection

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Colcher, D., Goel, A., Pavlinkova, G., Beresford, G., Booth, B., & Batra, S. K. (1999). Effects of genetic engineering on the pharmacokinetics of antibodies. Quarterly Journal of Nuclear Medicine, 43(2), 132-139.

Effects of genetic engineering on the pharmacokinetics of antibodies. / Colcher, D.; Goel, A.; Pavlinkova, G.; Beresford, G.; Booth, B.; Batra, Surinder Kumar.

In: Quarterly Journal of Nuclear Medicine, Vol. 43, No. 2, 19.07.1999, p. 132-139.

Research output: Contribution to journalReview article

Colcher, D, Goel, A, Pavlinkova, G, Beresford, G, Booth, B & Batra, SK 1999, 'Effects of genetic engineering on the pharmacokinetics of antibodies', Quarterly Journal of Nuclear Medicine, vol. 43, no. 2, pp. 132-139.
Colcher D, Goel A, Pavlinkova G, Beresford G, Booth B, Batra SK. Effects of genetic engineering on the pharmacokinetics of antibodies. Quarterly Journal of Nuclear Medicine. 1999 Jul 19;43(2):132-139.
Colcher, D. ; Goel, A. ; Pavlinkova, G. ; Beresford, G. ; Booth, B. ; Batra, Surinder Kumar. / Effects of genetic engineering on the pharmacokinetics of antibodies. In: Quarterly Journal of Nuclear Medicine. 1999 ; Vol. 43, No. 2. pp. 132-139.
@article{926872d39d144728ac074b76c94d1ffb,
title = "Effects of genetic engineering on the pharmacokinetics of antibodies",
abstract = "Monoclonal antibodies (MAbs) may be considered 'magic bullets' due to their ability to recognize and eradicate malignant cells. MAbs, however, have practical limitations for their rapid application in the clinics. The structure of antibody molecules can be engineered to modify functional domains such as antigen-binding sites and/or effector functions. Advances in genetic engineering have provided rapid progress in the development of new immunoglobulin constructs of MAbs with defined research and therapeutic application. Recombinant antibody constructs are being engineered, such as human-mouse chimeric, domain-dispositioned, domain-deleted, humanized and single-chain Fv fragments. Genetically-engineered antibodies differ in size and rate of catabolism. Pharmacokinetic studies show that the intact IgG (150 kD), enzymatically derived fragments Fab' (50 kD) and single chain Fv (28 kD) have different clearance rates. These antibody forms clear 50{\%} from the blood pool in 2.1 days, 30 minutes and 10 minutes, respectively. Genetically- engineered antibodies make anew class of immunotherapeutic tracers for cancer treatment.",
keywords = "Antibodies, Antibodies monoclonal, Colon carcinoma xenografts, Immunoglobulin fragments, Monoclonal biosynthesis, Radioimmunodetection",
author = "D. Colcher and A. Goel and G. Pavlinkova and G. Beresford and B. Booth and Batra, {Surinder Kumar}",
year = "1999",
month = "7",
day = "19",
language = "English (US)",
volume = "43",
pages = "132--139",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Effects of genetic engineering on the pharmacokinetics of antibodies

AU - Colcher, D.

AU - Goel, A.

AU - Pavlinkova, G.

AU - Beresford, G.

AU - Booth, B.

AU - Batra, Surinder Kumar

PY - 1999/7/19

Y1 - 1999/7/19

N2 - Monoclonal antibodies (MAbs) may be considered 'magic bullets' due to their ability to recognize and eradicate malignant cells. MAbs, however, have practical limitations for their rapid application in the clinics. The structure of antibody molecules can be engineered to modify functional domains such as antigen-binding sites and/or effector functions. Advances in genetic engineering have provided rapid progress in the development of new immunoglobulin constructs of MAbs with defined research and therapeutic application. Recombinant antibody constructs are being engineered, such as human-mouse chimeric, domain-dispositioned, domain-deleted, humanized and single-chain Fv fragments. Genetically-engineered antibodies differ in size and rate of catabolism. Pharmacokinetic studies show that the intact IgG (150 kD), enzymatically derived fragments Fab' (50 kD) and single chain Fv (28 kD) have different clearance rates. These antibody forms clear 50% from the blood pool in 2.1 days, 30 minutes and 10 minutes, respectively. Genetically- engineered antibodies make anew class of immunotherapeutic tracers for cancer treatment.

AB - Monoclonal antibodies (MAbs) may be considered 'magic bullets' due to their ability to recognize and eradicate malignant cells. MAbs, however, have practical limitations for their rapid application in the clinics. The structure of antibody molecules can be engineered to modify functional domains such as antigen-binding sites and/or effector functions. Advances in genetic engineering have provided rapid progress in the development of new immunoglobulin constructs of MAbs with defined research and therapeutic application. Recombinant antibody constructs are being engineered, such as human-mouse chimeric, domain-dispositioned, domain-deleted, humanized and single-chain Fv fragments. Genetically-engineered antibodies differ in size and rate of catabolism. Pharmacokinetic studies show that the intact IgG (150 kD), enzymatically derived fragments Fab' (50 kD) and single chain Fv (28 kD) have different clearance rates. These antibody forms clear 50% from the blood pool in 2.1 days, 30 minutes and 10 minutes, respectively. Genetically- engineered antibodies make anew class of immunotherapeutic tracers for cancer treatment.

KW - Antibodies

KW - Antibodies monoclonal

KW - Colon carcinoma xenografts

KW - Immunoglobulin fragments

KW - Monoclonal biosynthesis

KW - Radioimmunodetection

UR - http://www.scopus.com/inward/record.url?scp=0033058507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033058507&partnerID=8YFLogxK

M3 - Review article

C2 - 10429508

AN - SCOPUS:0033058507

VL - 43

SP - 132

EP - 139

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 2

ER -